tirzepatide compunded Addressing the Weight Loss Injectable

Zhang YL, Zhou C, Li XF, et al

In March, Roche and Zealand released Phase 2 clinical trial data for a once-weekly injection of petrelintide showing nearly 10% weight reduction among participants with minimal side effects

Anxiety often improves once your body adapts to the medication, typically within 24 weeks of dose stabilization

Androgenetic alopecia (pattern hair loss) is the most common form of hair loss in both men and women, driven by genetic sensitivity to DHT

Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a genetic condition predisposing to MTC